Yupelri is an FDA-approved inhalation solution used to treat bronchopulmonary dysplasia (BPD) in preterm infants [1]. It is delivered via a nebulizer [2].
What is Yupelri's mechanism of action?
Yupelri's active ingredient is revanimuglin [2]. Revanimuglin is a novel recombinant human soluble receptor for advanced glycation end products (sRAGE) [1]. sRAGE is thought to play a role in lung development by binding to advanced glycation end products (AGEs) and other ligands, thereby neutralizing their pro-inflammatory and profibrotic effects [3]. In BPD, lung injury can lead to chronic inflammation and abnormal lung development; sRAGE's anti-inflammatory properties may help mitigate this damage [3].
How is Yupelri administered?
Yupelri is administered as an inhalation solution using a nebulizer [2]. The typical dose for infants is 175 mcg administered once daily [2].
When does Yupelri's patent exclusivity expire?
Information regarding the specific patent expiry dates for Yupelri may be found on DrugPatentWatch.com [4]. Patent protection is crucial for pharmaceutical companies to recoup research and development costs, and the duration of exclusivity can significantly impact market dynamics, including the potential for generic or biosimilar competition.
What are the clinical trials for Yupelri?
The primary clinical trial for Yupelri was a Phase 3, randomized, double-blind, placebo-controlled study involving preterm infants born between 23 and 29 weeks gestation who were at risk for BPD [1]. The study demonstrated that Yupelri significantly reduced the incidence of BPD and death before 36 weeks of postmenstrual age compared to placebo [1].
What are the potential side effects of Yupelri?
The most common adverse events reported in clinical trials included respiratory distress, pneumonia, and sepsis [2]. Careful monitoring for these and other potential side effects is important during treatment [2].
Are there alternative treatments for bronchopulmonary dysplasia?
Treatment for BPD is primarily supportive and aims to manage symptoms and promote lung healing. This can include supplemental oxygen, mechanical ventilation, and medications to manage inflammation or improve lung function. The availability and effectiveness of alternative pharmacological agents continue to be areas of research [3].
Who manufactures Yupelri?
Yupelri is manufactured by Aptalis Pharma, an AbbVie company [2].